Physician profile
Seth Manning
NPI 1972242154
$1,052.58
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.71 · 2023: $629 · 2024: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233.02 | 2023-2024 | |
| Axsome Therapeutics, INC. | $144.87 | 2023-2024 | Sunosi |
| Mylan Specialty L.P. | $130.89 | 2023-2024 | Yupelri |
| Novo Nordisk INC | $109.05 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $100.04 | 2023-2024 | Mounjaro, Trulicity |
| Pfizer INC. | $60.89 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.41 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $43.72 | 2024 | Farxiga |
| Astellas Pharma US INC | $33.51 | 2024 | Veozah |
| Bausch Health US, LLC | $29.94 | 2024 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $27.71 | 2022 | |
| Lundbeck LLC | $20.78 | 2024 | Rexulti |
| Boston Scientific Corporation | $18.13 | 2023 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.40 | 2024 | Trulance, Xifaxan |
| Idorsia Pharmaceuticals US INC | $14.96 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.85 | 2024 | Otezla, Repatha |
| Corium, LLC | $2.41 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.